{"resourceType":"ValueSet","id":"2.16.840.1.113883.3.464.1003.110.11.1157","meta":{"versionId":"12","lastUpdated":"2021-09-23T01:03:11.000-04:00"},"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1157","version":"20210923","name":"HiB Vaccine (4 dose schedule) Administered","status":"active","date":"2021-09-23T01:03:11-04:00","publisher":"NCQA PHEMUR","compose":{"include":[{"system":"http://snomed.info/sct","version":"http://snomed.info/sct/731000124108/version/20220301","concept":[{"code":"310306005","display":"Administration of first dose of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type B and Human poliovirus antigens (procedure)"},{"code":"310307001","display":"Administration of second dose of Vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type B and Human poliovirus antigens (procedure)"},{"code":"310308006","display":"Administration of third dose of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type B and Human poliovirus antigens (procedure)"},{"code":"312870000","display":"Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type B and Human poliovirus antigens (procedure)"},{"code":"414001002","display":"Administration of vaccine product containing only five component acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type B and inactivated whole Human poliovirus antigens (procedure)"},{"code":"414259000","display":"Administration of first dose of vaccine product containing only five component acellular Bordetella pertussis, Clostridium tetani, Corynebacterium diphtheriae, Haemophilus influenzae type B and inactivated whole Human poliovirus antigens (procedure)"},{"code":"415507003","display":"Administration of second dose of vaccine product containing only five component acellular Bordetella pertussis, Clostridium tetani, Corynebacterium diphtheriae, Haemophilus influenzae type B and inactivated whole Human poliovirus antigens (procedure)"},{"code":"415712004","display":"Administration of third dose of vaccine product containing only five component acellular Bordetella pertussis, Clostridium tetani, Corynebacterium diphtheriae, Haemophilus influenzae type B and inactivated whole Human poliovirus antigens (procedure)"}]}]},"expansion":{"identifier":"urn:uuid:ff439716-9597-432d-8b3a-2b92cf765851","timestamp":"2022-06-10T08:17:15-04:00","total":8,"offset":0,"parameter":[{"name":"count","valueInteger":1000},{"name":"offset","valueInteger":0}],"contains":[{"system":"http://snomed.info/sct","version":"http://snomed.info/sct/731000124108/version/20220301","code":"310306005","display":"Administration of first dose of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type B and Human poliovirus antigens (procedure)"},{"system":"http://snomed.info/sct","version":"http://snomed.info/sct/731000124108/version/20220301","code":"310307001","display":"Administration of second dose of Vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type B and Human poliovirus antigens (procedure)"},{"system":"http://snomed.info/sct","version":"http://snomed.info/sct/731000124108/version/20220301","code":"310308006","display":"Administration of third dose of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type B and Human poliovirus antigens (procedure)"},{"system":"http://snomed.info/sct","version":"http://snomed.info/sct/731000124108/version/20220301","code":"312870000","display":"Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type B and Human poliovirus antigens (procedure)"},{"system":"http://snomed.info/sct","version":"http://snomed.info/sct/731000124108/version/20220301","code":"414001002","display":"Administration of vaccine product containing only five component acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type B and inactivated whole Human poliovirus antigens (procedure)"},{"system":"http://snomed.info/sct","version":"http://snomed.info/sct/731000124108/version/20220301","code":"414259000","display":"Administration of first dose of vaccine product containing only five component acellular Bordetella pertussis, Clostridium tetani, Corynebacterium diphtheriae, Haemophilus influenzae type B and inactivated whole Human poliovirus antigens (procedure)"},{"system":"http://snomed.info/sct","version":"http://snomed.info/sct/731000124108/version/20220301","code":"415507003","display":"Administration of second dose of vaccine product containing only five component acellular Bordetella pertussis, Clostridium tetani, Corynebacterium diphtheriae, Haemophilus influenzae type B and inactivated whole Human poliovirus antigens (procedure)"},{"system":"http://snomed.info/sct","version":"http://snomed.info/sct/731000124108/version/20220301","code":"415712004","display":"Administration of third dose of vaccine product containing only five component acellular Bordetella pertussis, Clostridium tetani, Corynebacterium diphtheriae, Haemophilus influenzae type B and inactivated whole Human poliovirus antigens (procedure)"}]}}